Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany.

M. Rohrbacher, U. Berger, A. Hochhaus, G. Metzgeroth, K. Adam, T. Lahaye, S. Saussele, J. Hasford, H. Heimpel, Rüdiger Hehlmann

Blood (2007) 110 (11): 2955.

https://doi.org/10.1182/blood.V110.11.2955.2955

Published: 2007

Journal Articles

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

Michele Baccarani, H.M. Kantarjian, J.F. Apperley, J.H. Lipton, B. Druker, A. Countouriotis, R. Ezzeddine, A. Hochhaus

Blood (2006) 108 (11): 164.

https://doi.org/10.1182/blood.V108.11.164.164

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

Giovanni Martinelli, A. Hochhaus, S. Coutre, J.F. Apperley, N. Shah, A. Gollerkeri, P. Agarwal, O.G. Ottmann

Blood (2006) 108 (11): 745.

https://doi.org/10.1182/blood.V108.11.745.745

Published: 2006

Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Hagop M. Kantarjian, MD, O. Ottman, MD, Jorge Cortes, MD, M. Wassman, MD, L. Wunderle, MD, K. Bhalla, MD, D. Jones, MD, A. Hochhaus, MD, P. Rae, L. Alland, MD, M. Dugan, MD, M. Albitar, MD, Francis Giles, MD

Blood (2005) 106 (11): 37.

https://doi.org/10.1182/blood.V106.11.37.37

Published: 2005

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Oliver G. Ottmann, G. Martinelli, H. Dombret, H. Kantarjian, A. Hochhaus, B. Simonsson, A. Aloe, A. Apanovitch, N. Shah

Blood (2005) 106 (11): 42.

https://doi.org/10.1182/blood.V106.11.42.42

Published: 2005

Journal Articles

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Blood (2005) 106 (11): 483.

https://doi.org/10.1182/blood.V106.11.483.483

Published: 2005

Journal Articles

Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial.

Martin C. Mueller, MD, P. Paschka, MD, T. Lahaye, MD, Ch. Lorentz, MD, N. Gattermann, MD, D. Niederwieser, MD, G. Ehninger, MD, St Fruehauf, MD, A. Neubauer, MD, Th. Fischer, MD, B. Schultheis, MD, S. Kreil, MD, U. Haus, PhD, R. Hehlmann, MD, A. Hochhaus, MD, the German CML Study Group

Blood (2004) 104 (11): 1003.

https://doi.org/10.1182/blood.V104.11.1003.1003

Published: 2004

Journal Articles

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

G. Hess, MD, D. Bunjes, MD, W. Siegert, MD, R. Schwerdtfeger, MD, G. Ledderose, MD, B. Waßmann, MD, G. Kobbe, MD, M. Bornhäuser, MD, A. Hochhaus, MD, A. J. Ullmann, MD, T. Kindler, MD, H. Geschaidmeier, PhD, C. Huber11, MD, T. Fischer12, MD

Blood (2004) 104 (11): 1004.

https://doi.org/10.1182/blood.V104.11.1004.1004

Published: 2004

Journal Articles

Molecular investigation of secondary chronic myeloid leukemia [letter]

RC Aguiar, H Sill, A Hochhaus, JM Goldman, NC Cross

Blood (1996) 88 (7): 2808–2809.

https://doi.org/10.1182/blood.V88.7.2808.bloodjournal8872808

Published: 1996

Journal Articles

A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia

A Hochhaus, A Reiter, H Skladny, JV Melo, C Sick, U Berger, JQ Guo, RB Arlinghaus, R Hehlmann, JM Goldman, NC Cross

Blood (1996) 88 (6): 2236–2240.

https://doi.org/10.1182/blood.V88.6.2236.bloodjournal8862236

Published: 1996

Journal Articles

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias

F van Rhee, A Hochhaus, F Lin, JV Melo, JM Goldman, NC Cross

Blood (1996) 87 (12): 5213–5217.

https://doi.org/10.1182/blood.V87.12.5213.bloodjournal87125213

Published: 1996

Journal Articles

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction

A Hochhaus, F Lin, A Reiter, H Skladny, PJ Mason, F van Rhee, PC Shepherd, NC Allan, R Hehlmann, JM Goldman, NC Cross

Blood (1996) 87 (4): 1549–1555.

https://doi.org/10.1182/blood.V87.4.1549.bloodjournal8741549

Published: 1996

Journal Articles

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]

R Hehlmann, H Heimpel, J Hasford, HJ Kolb, H Pralle, DK Hossfeld, W Queisser, H Loffler, A Hochhaus, B Heinze

Blood (1994) 84 (12): 4064–4077.

https://doi.org/10.1182/blood.V84.12.4064.bloodjournal84124064

Published: 1994

NARROW

Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany.

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial.

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

Molecular investigation of secondary chronic myeloid leukemia [letter]

A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only